PER-019-16已完成未知

A PHASE 2B STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VRC01 BROADLY NEUTRALIZING MONOCLONAL ANTIBODY IN REDUCING ACQUISITION OF HIV-1 INFECTION AMONG MEN AND TRANSGENDER PERSONS WHO HAVE SEX WITH ME

Instituto Nacional de Alergias y Enfermedades Infecciosas (NIAID). EEUU,0 个研究点目标入组 1,131 人开始时间: 2016年8月9日最近更新: 2023年9月4日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 1,131

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•HEALTHY HUMAN VOLUNTEERS
•1.Age of 18 to 50 years
•2.Access to a participating CRS and willingness to be followed for the planned duration of the study
•3.Ability and willingness to provide informed consent
•4.Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first infusion with verbal demonstration of understanding of all questionnaire items answered incorrectly
•5.Agrees not to enroll in another study of an investigational research agent for the duration of the participant’s trial participation
•6.Good general health as shown by medical history, physical exam, and screening laboratory tests
•HIV-Related Criteria:
•7.Willingness to receive HIV test results
•8.Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling
•9.Persons born Male or identifying as Transgender (TG) who, in the 6 months prior to randomization, experienced 1 or both of the following HIV risk criteria:
•Condomless anal intercourse with 1 or more male or transgender partner(s)
•Anal intercourse with 2 or more male or transgender partners
•Male-to-female and female-to-male TG volunteers are eligible. Receipt of hormonal therapy does not make a TG volunteer ineligible.
•Volunteers who have been in a monogamous relationship with an HIV-1 seronegative partner for > 1 year are excluded.
•Laboratory Inclusion Values
•10.Hemoglobin (Hgb) ≥ 10.5 g/dL for volunteers who were born female, ≥ 13.0 g/dL for volunteers who were born male
•11.Platelets ≥ 100,000 cells/mm3
•12.ALT < 2.5 times the institutional upper limit of normal and creatinine ≤ 1.25 times the institutional upper limit of normal
•13.HIV uninfected, as defined in the SSP, within 30 days prior to enrollment
•14.Negative, trace, or 1+ (30 gL for semi-quantitative) urine protein by dipstick
•Reproductive Status
•15.Volunteers capable of becoming pregnant: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed at the screening visit and prior to infusion on the day of initial infusion. Persons who are NOT capable of becoming pregnant due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records) are not required to undergo pregnancy testing.
•16.Reproductive status: A volunteer who is capable of becoming pregnant must agree to consistently use effective contraception (see Appendix B, , and SSP) for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol clinic visit.
•17.Volunteers capable of becoming pregnant must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit.

排除标准

•1.Investigational research agents received within 30 days before first infusion
•2.Body mass index (BMI) ≥ 40
•3.Pregnant or breastfeeding
•4.Any reactive, indeterminate, or positive HIV test, even if subsequent testing indicates that the individual is not HIV infected.
•5.HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 704/HPTN 085 PSRT will determine eligibility on a case-by-case basis.
•Immune System
•6.Serious adverse reactions to VRC01 formulation components such as sodium citrate, sodium chloride, and L-arginine hydrochloride, including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.
•7.Autoimmune disease, including Type I diabetes mellitus (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require consistent immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate reactogenicity and AE assessments)
•8.Immunodeficiency syndrome
•Clinically significant medical conditions
•9.Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
•Any contraindication to repeated infusions or blood draws, including inability to establish venous access;
•A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer’s health or well-being during the study period; or
•A condition or process for which signs or symptoms could be confused with reactions to VRC01.
•10.Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or infusion reactions, or a volunteer’s ability to give informed consent
•11.Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
•12.Asthma, other than mild, well-controlled asthma
•13.Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
•14.Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator’s estimation, has a reasonable assurance of sustained cure. or who is unlikely to experience recurrence of malignancy during the period of the study)
•15.Seizure disorder: History of seizure(s) within past three years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
•16.History of hereditary angioedema, acquired angioedema, or idiopathic angioedema
•17.History of organ or tissue transplantation
•18.Known hepatic or renal dysfunction

研究者

发起方

Instituto Nacional de Alergias y Enfermedades Infecciosas (NIAID). EEUU,

相似试验

进行中（未招募）

1 期

EUCTR2016-003579-22-ESRoche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche120

进行中（未招募）

1 期

EUCTR2016-003579-22-DEF. Hoffmann-La Roche Ltd55

进行中（未招募）

1 期

EUCTR2016-003579-22-LVF. Hoffmann-La Roche Ltd120

进行中（未招募）

1 期

A Study Exploring the Safety and Efficacy of Atezolizumab Administered in Combination with Obinutuzumab or Rituximab Anti-CD20 Therapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenstr¿m MacroglobulinemiaRelapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenstr¿m Macroglobulinemia (WM)MedDRA version: 21.1Level: LLTClassification code 10054698Term: Waldenstrom's macroglobulinemia refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026800Term: Mantle cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077534Term: Marginal zone lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10077533Term: Marginal zone lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054697Term: Waldenstrom's macroglobulinemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA v

EUCTR2016-003579-22-ITF. HOFFMANN - LA ROCHE LTD.55

进行中（未招募）

1 期

A Study Exploring the Safety and Efficacy of Atezolizumab Administered in Combination with Obinutuzumab or Rituximab Anti-CD20 Therapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenström MacroglobulinemiaRelapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM)MedDRA version: 20.0Level: LLTClassification code 10054697Term: Waldenstrom's macroglobulinemia recurrentSystem Organ Class: 100000013195MedDRA version: 20.0Level: LLTClassification code 10054698Term: Waldenstrom's macroglobulinemia refractorySystem Organ Class: 100000013206MedDRA version: 20.0Level: PTClassification code 10077534Term: Marginal zone lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077533Term: Marginal zone lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026800Term: Mantle cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-003579-22-GRF. Hoffmann-La Roche Ltd120